Literature DB >> 10352314

Cellular immunity to beta 2-glycoprotein-1 in patients with the antiphospholipid syndrome.

S Visvanathan1, H P McNeil.   

Abstract

Patients with antiphospholipid syndrome (APS) suffer recurrent thromboses, thrombocytopenia, and/or fetal loss in association with Abs that can be detected in phospholipid-dependent assays. Despite the name, the Igs associated with APS are predominantly directed against epitopes on phospholipid-binding plasma proteins, such as beta 2-glycoprotein-1 (beta 2GP1) and prothrombin. The aim of this study was to examine the cellular immune response to beta 2GP1 in patients with APS. Using a serum-free stimulation assay, PBMCs from 8 of 18 patients with APS proliferated to purified beta 2GP1 or to the beta 2GP1 present in serum, whereas no stimulation was observed by PBMCs from healthy individuals, patients with other autoimmune diseases, or anticardiolipin Ab-positive patients without histories of thromboses or fetal loss. The immune response was Ag-specific, requiring class II molecules, CD4+ T cells, and APCs, and was associated with a selective expansion of CD4+ but not CD8+ T cells. The proliferating T cells produced IFN-gamma but not IL-4, indicating a bias toward a type 1 immune response. Chronic low grade stimulation of autoreactive beta 2GP1-specific, IFN-gamma-producing Th1 CD4+ T cells may contribute to the high risk of thromboses and pregnancy failure in patients with APS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352314

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.

Authors:  Imre Farkas; Lajos Baranyi; Yasushige Ishikawa; Noriko Okada; Csaba Bohata; Denes Budai; Atsuo Fukuda; Masaki Imai; Hidechika Okada
Journal:  J Physiol       Date:  2002-03-01       Impact factor: 5.182

2.  β2-Glycoprotein I-specific T cells are associated with epitope spread to lupus-related autoantibodies.

Authors:  David Salem; Rebecca Subang; Yuka Okazaki; Patrick Laplante; Jerrold S Levine; Masataka Kuwana; Joyce Rauch
Journal:  J Biol Chem       Date:  2015-01-02       Impact factor: 5.157

Review 3.  Systemic antiphospholipid syndrome and atherosclerosis.

Authors:  Luis J Jara; Gabriela Medina; Olga Vera-Lastra
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

4.  T cells demonstrate a Th1-biased response to native beta2-glycoprotein I in a murine model of anti-phospholipid antibody induction.

Authors:  Tanya Tolomeo; Angela Rico De Souza; Evan Roter; Mélanie Dieudé; Pascal Amireault; Rebecca Subang; Jerrold S Levine; Joyce Rauch
Journal:  Autoimmunity       Date:  2009-05       Impact factor: 2.815

Review 5.  Antiphospholipid syndrome: an overview.

Authors:  John G Hanly
Journal:  CMAJ       Date:  2003-06-24       Impact factor: 8.262

6.  Cloning and characterization of the human beta2-glycoprotein I (beta2-GPI) gene promoter: roles of the atypical TATA box and hepatic nuclear factor-1alpha in regulating beta2-GPI promoter activity.

Authors:  Hsueh-Hsiao Wang; An-Na Chiang
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

Review 7.  Antiphospholipid antibody effects on monocytes.

Authors:  Alisa S Wolberg
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

Review 8.  β2-Glycoprotein I-Reactive T Cells in Autoimmune Disease.

Authors:  Joyce Rauch; David Salem; Rebecca Subang; Masataka Kuwana; Jerrold S Levine
Journal:  Front Immunol       Date:  2018-12-10       Impact factor: 7.561

9.  Altered Th17/Treg Ratio in Peripheral Blood of Systemic Lupus Erythematosus but Not Primary Antiphospholipid Syndrome.

Authors:  Lorena Álvarez-Rodríguez; Víctor Martínez-Taboada; Jaime Calvo-Alén; Iñaki Beares; Ignacio Villa; Marcos López-Hoyos
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.